Mangoceuticals Develops Oral GLP-1s: Stock Soars
Portfolio Pulse from Erica Kollmann
Mangoceuticals, Inc. (NASDAQ:MGRX) shares surged after the company announced the development of oral formulations of Semaglutide and Tirzepatide for weight management. The products, named 'Slim' and 'Trim', are expected to be available in the 3rd quarter of the year.
May 21, 2024 | 2:56 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Mangoceuticals shares surged 247% after announcing the development of oral formulations of Semaglutide and Tirzepatide, expected to be available in Q3.
The announcement of new products 'Slim' and 'Trim' has generated significant investor interest, as evidenced by the heavy trading volume and substantial price increase. The products target the weight management market, which has high demand, potentially leading to increased revenues for Mangoceuticals.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100